IHC workup of lung neuroendocrine neoplasms
June 2026—The immunostaining landscape for lung neuroendocrine tumors continues to evolve, and Humberto Trejo Bittar, MD, in a CAP25 lung cancer session last fall, captured where it stands.
Webinars and Sponsored Roundtables — Register Now
Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience
CAP TODAY does not endorse any of the products or services named within. The roundtable is made possible by a special educational grant from Tosoh Bioscience Inc.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.
Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from OncoLens and Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The roundtable is made possible by a special educational grant from Pillar Biosciences.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 1, 2026 1 PM-2 PM ET
This presentation will explore the value of in-house CGP, offer insights into the benefits and drawbacks of incorporation, and provide information about important practical factors when considering in-house implementation of CGP.
Webinar presenter Allison M. Cushman-Vokoun, MD, PhD, FCAP, Medical Director, Molecular Diagnostics and Personalized Medicine Laboratory, Director, Division of Diagnostic Molecular Pathology and Human Genetics, Henry F. Krous Professor of Pathology, University of Nebraska Medical Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Illumina.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
ARTICLES
Lab leaders weigh alternative revenue models
June 2026—Alternative revenue models for laboratories, specifically laboratory testing for functional health and other health care practices that traditionally haven’t been part of conventional medicine, came up in a May 6 online Compass Group roundtable, led by CAP TODAY publisher Bob McGonnagle.
Health insurer consolidation: a case of the tail wagging the dog
June 2026—The primary reason for health insurance is to help patients pay for medical care when they need it. Beneficiaries pay their premiums when healthy to receive payouts when sick. Sounds simple, and at its inception it was. Dallas, Tex., gave birth in 1929 to the precursor of the Blue Cross system. Plan members paid in, and if hospitalization was needed, care was rendered and fees were paid by the community pool. But we’ve come a long way since then.
AMP case report: Ultra-hypermutated colorectal adenocarcinoma identified at relapse
June 2026—We present the case of a 75-year-old woman with a history of a pT4 colorectal adenocarcinoma who was status-post right hemicolectomy two years prior to the current care episode. She returned for urgent medical evaluation of recurrent abdominal pain, was diagnosed with a small bowel obstruction, and underwent exploratory laparotomy with small bowel resection and primary anastomosis.
HER2 scoring in gastric cancer and other solid tumors
June 2026—How and why gastric cancer scoring for HER2 positivity differs from breast cancer scoring was the topic of a CAP TODAY webinar early this year presented by Josef Rüschoff, MD, of Kassel, Germany.
Instruments, test consolidation, and clinical needs
June 2026—Instrumentation for all laboratory testing sites—large and small—was the roundtable topic on April 21 when representatives of Roche, Beckman Coulter, and Siemens Healthineers met online with Moira Larsen, MD, MBA, of MedStar, and Joe Baker of Baylor Scott & White. CAP TODAY publisher Bob McGonnagle led, with questions about, among other things, AI, testing consolidation, what laboratories expect of vendors, and what laboratories are willing to contribute to the partnership. “We’re happy to help figure out what the bugs are,” Baker says of new instrumentation.
In support of infectious disease diagnostics and public health
June 2026—CAP TODAY publisher Bob McGonnagle spoke on March 12 with Jessica Van Allen, PhD, technical support lead for ZeptoMetrix, and Jesse M. Young, PhD, medical director for TriCore Research Institute’s research and clinical trials department and director of point-of-care testing. Dr. Young is also clinical assistant professor at the University of New Mexico.
Bob McGonnagle: Dr. Young, tell us about TriCore and the laboratories you oversee.
Dr. Young (TriCore): TriCore Reference Laboratory is a full-service diagnostic laboratory. The core laboratory offers about 2,900 test codes and has a modality similar to that of Labcorp and Quest, but we’re focused on New Mexican populations. We serve most of the hospitals in the area and have statewide collection sites whereby we’re trying to expand health care and provide coverage for our communities so everyone in the state has access to health care near their home instead of having to drive six hours to the nearest collection site, drive home, and then be called back for a critical value. Continue reading …
Watch the full conversation:
This roundtable discussion is sponsored by ZeptoMetrix.
ESR1 mutation testing questions follow trial
May 2026—When it comes to cancer mutations, there are big fish in little ponds, and little fish in big ponds, and big fish in big ponds, and little fish in little ponds. The ESR1 mutation and its emergence in advanced breast cancer is still deciding what stripe of fish it is—or rather, breast specialists, researchers, and the FDA are in the midst of figuring out potentially important uses …
Forge ahead or hold on HPV self-collection
May 2026—Two years after the Food and Drug Administration approved the first HPV self-collection devices, physicians and cervical cancer prevention advocates are debating the best use for the new screening option.
Risk management elevated to more formal framework
May 2026—In the laboratory general accreditation checklist in the 2025 edition, released last December, is new emphasis on a prospective risk assessment process in the laboratory’s quality management …